 |
|
Questionable Efficacy for Naltrexone in Patients With Asp40—Reply
Raymond F. Anton, MD;
Gabor Oroszi, MD, PhD;
Stephanie O’Malley, PhD;
David Couper, PhD;
Robert Swift, MD, PhD;
Helen Pettinati, PhD;
David Goldman, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We thank Dr Mattes for his thoughts about our study that reported an interaction of the µ-opiate receptor polymorphism Asn40Asp with naltrexone on treatment response in alcohol dependence.1 Because the field is early in investigating the effect of this polymorphism on alcohol effects and on its pharmacogenetic interactions, there is ample room for thoughtful dialogue.
Dr Mattes is primarily concerned about our explanation as to why the positive gene x naltrexone interaction was only observed in the group receiving MM alone and not in those who received a more intensive CBI in addition to MM. In essence, Dr Mattes suggests that since CBI in its own right was "not very effective," the explanation that CBI could wash out or override any direct naltrexone effect . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
An Evaluation of µ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study
Raymond F. Anton, Gabor Oroszi, Stephanie O’Malley, David Couper, Robert Swift, Helen Pettinati, and David Goldman
Arch Gen Psychiatry. 2008;65(2):135-144.
ABSTRACT
| FULL TEXT
RELATED LETTER
Questionable Efficacy for Naltrexone in Patients With Asp40
Jeffrey A. Mattes
Arch Gen Psychiatry. 2009;66(7):796.
EXTRACT
| FULL TEXT
|
